Form 4 Filing: Shawver Laura Acquires Stock Option in ARS Pharmaceuticals, Inc.

This filing details a Form 4 submission by Shawver Laura, a director at ARS Pharmaceuticals, Inc. (NASDAQ: SPRY). On June 24, 2026, Ms. Laura acquired a stock option to purchase 30,000 shares of the company's Common Stock at an exercise price of $10.54 per share. The option vests fully on the earlier of June 24, 2027, or the date of the Issuer's 2027 annual meeting of stockholders. Following this transaction, Ms. Laura holds 30,000 shares subject to this option. The filing was signed on June 26, 2026, by Kathleen Scott as Attorney-in-Fact for Ms. Laura. The option has an expiration date of June 23, 2036.